Read More

Cartesian Therapeutics Announces Approval Of Conversion Of Series A Convertible Preferred Stock And Plans To Effect 1-For-30 Reverse Stock Split Effective After The Closing Of Trading Hours On April 4, 2024

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced results from a special meeting of stockholders held

RNAC